Nasdaq · CIK 0001348362
LEXX Lexaria Bioscience Corp.
Insider trading from SEC Form 4. Last filing Mar 18, 2026. Close $3.32 on Oct 9, 2026, +20% from the 52-week low and -83% from the high.
In brief
Lexaria Bioscience Corp. (LEXX) has 20 SEC Form 4 filings on file from 9 insiders, the latest filed on Mar 18, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at LEXX. The newest: Christopher Bunka (Chief Executive Officer) bought $25k of stock on Jul 29, 2025, filed Jul 30, 2025, scored 56 (moderate). The largest of the 6 shown: Richard Christopher (Chief Executive Officer) bought $118k on Dec 2, 2024, scored 43 (moderate). 5 insiders bought within 14 days of each other around Jul 29, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Lexaria Bioscience Corp., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Christopher Bunka Chief Executive Officer buy | $25k 27,500 shares | +11% | +9% from low-75% from high | |
| 64Notable | Richard Christopher Chief Executive Officer buy | $14k 15,000 shares | +30% | +9% from low-75% from high | |
| 56Moderate | Vanessa Carle Secretary buy | $683 750 shares | - | +9% from low-75% from high | |
| 61Notable | John Martin Docherty President & CSO buy | $4,989 5,376 shares | - | +9% from low-75% from high | |
| 54Moderate | William Edward McKechnie director buy | $4,532 5,000 shares | +38% | +9% from low-75% from high | |
| 43Moderate | Richard Christopher Chief Executive Officer buy | $118k 50,000 shares | - | - |
Transactions
Every row filed, 22 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Christopher Bunka Chief Executive Officer | GGift common shares | -100,000 | $0.00 | $0 | 273,543 | Mar 18, 2026 |
| Jul 29, 2025 | Vanessa Carle Secretary | POpen-market purchase common shares | +750 | $0.91 | $683 | 750 | Jul 30, 2025 |
| Jul 29, 2025 | Richard Christopher Chief Executive Officer | POpen-market purchase common shares | +15,000 | $0.91 | $14k | 65,000 | Jul 30, 2025 |
| Jul 29, 2025 | John Martin Docherty President & CSO | POpen-market purchase common shares | +5,376 | $0.93 | $4,989 | 5,376 | Jul 30, 2025 |
| Jul 29, 2025 | William Edward McKechnie director | POpen-market purchase common shares | +5,000 | $0.91 | $4,532 | 18,191 | Jul 30, 2025 |
| Jul 29, 2025 | Christopher Bunka Chief Executive Officer | POpen-market purchase common sharesindirect: Private Holding Company | +15,600 | $0.92 | $14k | 270,012 | Jul 30, 2025 |
| Jul 30, 2025 | Christopher Bunka Chief Executive Officer | POpen-market purchase common sharesindirect: Private Holding Company | +11,900 | $0.91 | $11k | 281,912 | Jul 30, 2025 |
| May 15, 2025 | Michael Elliot Shankman Chief Financial Officer | AGrant or award Stock Optionsderivative | +50,000 | $0.00 | $0 | 100,000 | May 16, 2025 |
| May 15, 2025 | Baljinder Bhullar director | AGrant or award Stock Optionsderivative | +11,000 | $0.00 | $0 | 11,000 | May 16, 2025 |
| May 15, 2025 | Richard Christopher Chief Executive Officer | AGrant or award Stock Optionsderivative | +150,000 | $0.00 | $0 | 350,000 | May 16, 2025 |
| May 15, 2025 | Vanessa Carle Secretary | AGrant or award Stock Optionsderivative | +15,000 | $0.00 | $0 | 75,000 | May 16, 2025 |
| May 15, 2025 | John Martin Docherty President | AGrant or award Stock Optionsderivative | +150,000 | $0.00 | $0 | 310,834 | May 16, 2025 |
| May 15, 2025 | Albert L Reese Jr director | AGrant or award Stock Optionsderivative | +11,000 | $0.00 | $0 | 43,000 | May 16, 2025 |
| May 15, 2025 | Christopher Bunka Chief Executive Officer | AGrant or award Stock Optionsderivative | +11,000 | $0.00 | $0 | 184,834 | May 16, 2025 |
| May 15, 2025 | Nicholas W Baxter director | AGrant or award Stock Optionsderivative | +11,000 | $0.00 | $0 | 63,000 | May 16, 2025 |
| May 15, 2025 | William Edward McKechnie director | AGrant or award Stock Optionsderivative | +11,000 | $0.00 | $0 | 63,000 | May 16, 2025 |
| Jan 7, 2025 | Christopher Bunka Chief Executive Officer | AGrant or award Restricted Stock Award | +100,000 | $0.00 | $0 | 373,543 | Jan 10, 2025 |
| Dec 2, 2024 | Richard Christopher Chief Executive Officer | POpen-market purchase common shares | +22,828 | $2.24 | $51k | 22,828 | Dec 3, 2024 |
| Dec 3, 2024 | Richard Christopher Chief Executive Officer | POpen-market purchase common shares | +27,172 | $2.47 | $67k | 50,000 | Dec 3, 2024 |
| Oct 26, 2023 | Vanessa Carle Secretary | AGrant or award Stock Optionsderivative | +12,500 | $0.00 | $0 | 52,567 | Nov 1, 2023 |
| Oct 26, 2023 | John Martin Docherty President | AGrant or award Stock Optionsderivative | +30,000 | $0.00 | $0 | 124,668 | Oct 30, 2023 |
| Oct 26, 2023 | Christopher Bunka Chief Executive Officer | AGrant or award Stock Optionsderivative | +30,000 | $0.00 | $0 | 131,001 | Oct 30, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Christopher BunkaChief Executive Officer
- Nicholas W Baxterdirector
- Baljinder Bhullardirector
- Richard ChristopherChief Executive Officer
- Vanessa CarleSecretary
- John Martin DochertyPresident
- William Edward McKechniedirector
- Albert L Reese Jrdirector
- Michael Elliot ShankmanChief Financial Officer
Questions about LEXX
Answered from the filings on this page, as of the latest one.
Are insiders buying LEXX?
No. In the last 90 days no insider at Lexaria Bioscience Corp. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade LEXX on the open market?
Christopher Bunka (Chief Executive Officer) bought $25k of LEXX on Jul 29, 2025 and filed the Form 4 on Jul 30, 2025. InsiderTell scored 56 (moderate), with 5 insiders on the same side within 14 days.
How many insiders file Form 4 at Lexaria Bioscience Corp.?
9 people have filed a Form 4 at Lexaria Bioscience Corp., among them Christopher Bunka (Chief Executive Officer), Nicholas W Baxter (director), Baljinder Bhullar (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.